🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FLT3-ITD MRD can identify which patients benefit from gilteritinib maintenance. ow.ly/B79T50VPLu4 #clinicaltrialsandobservations #myeloidneoplasia

Our May 2025 print issue is out now!! 🎉 This jam-packed issue includes a feature on diet and blood cancer risk, a Get to Know interview with Kerry Rogers, a fellows spotlight on Julie Braish and Sankalp Arora, MD, and much more. 📚 Don't miss it! buff.ly/Pv6vgNz

MD Anderson Fellow Dives Deep into the Unknowns of FLT3-TKD-Mutated AML bloodcancerstoday.com/post/md-anders… Thanks for the feature Blood Cancers Today! #leusm #MedTwitter Naval Daver, M.D. Naveen Pemmaraju, MD

Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring |American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/full/10.10…

Delighted to share our study out in Cell Stem Cell today from the dream team Elli Papaemmanuil, PhD Iannis Aifantis AK Eisfeld Dan Landau! We profiled IDH-mutated AML patients to define how IDH and co-mutations shape the disease at baseline and responses to IDH-inhibitors. 🧵👇

An excellent start to the #westernbloodconference with keynote speaker Dr. Craig Jordan discussing #metabolomics and the potential resurgence of mitoxantrone in AML! Adrienne Dorrance Elf Lab 🇺🇦🏳️‍🌈🏳️‍⚧️⚧️👊🏾👊🏽🌈🟧 Daniel Pollyea #leusm

End to an amazing 1st Western Blood Conference Sundance Resort in Utah! Outstanding talks by Daniel Pollyea Dr. Uma Borate: Associate Professor Curtis Lachowiez Elf Lab 🇺🇦🏳️‍🌈🏳️‍⚧️⚧️👊🏾👊🏽🌈🟧 Adrienne Dorrance among others! Off to #ASCO25 now! 📸 slide showing genomic complexity of AML; the beautiful Utah landscape #leusm

The NextGen Disruptor Award, given in partnership w/ Healio Community, goes to Nazli Dizman! Dr. Dizman is... 💚 a second-year fellow at MD Anderson Cancer Center 💚 a voice for international medical graduates 💚 contributing to renal cell carcinoma research Congratulations!

Rebekka Schneider Tyler Parsons PedsHemeDoc Anna E. Beaudin Nate Krah Dr. Uma Borate: Associate Professor Curtis Lachowiez MPN Research Foundation Stephen Sykes Sankalp Arora, MD Afaf Osman, MD Jordan Lab and more!!

Thank you Ryan Denu, MD, PhD ! Come say hi at poster board 155! We saw FLT3 loss and emergent non-FLT3 mutations in about 50% of our frontline FLT3 AML cohort at relapse after FLT3i based therapy. #leusm Nicholas Short MD Naval Daver, M.D.

“Not everything that counts can be counted. Not everything that can be counted, counts.” -Mark Lewis, MD, FASCO In oncology, metrics matter. But meaning or time or values? You can’t quantify those. That’s why shared decision-making isn’t just a buzzword; it’s the ENTIRE point. #ASCO25

#ASCO25 #leusm #onclive #MedTwitter

#ASCO25 #AML #leusm ASCERTAIN-V Trial presented by Dr. Zeidan Amer Zeidan MBBS,MHS ‏عامر زيدان all oral regimen (oral decitabine/cedazuridine plus venetoclax) for AML ineligible to IC. 1. CR/CRh 51.5%, CR/CRi 63% 2. mOS 15.5 months Results comparable to #VIALE_A trial with all oral regimen.

#ASCO25 #leusm #AML KOMET-001 Trial in RR NPM1m AML. 1. CR/CRh ~ 25% 2. mOS 6.2; responders 16.4mo, non-responders ~ 3.5mo 3. All grade DS 25%, QTc prolongation 3%.

Impressive results of 7+3 + Ziftomenib in newly diagnosed AML patients with NPM1m or KMT2Ar presented by Harry Erba. We are embarking on a new era of menin inhibitors in combination with frontline therapy in newly Dx AML w/ NPM1m or KMT2Ar. European Hematology Association #EHA25

Excellent oral abstract session on innovative treatments for #MPNSM at #EHA25! Robust early data on elritercept for anemia of MF, nuvisertib for MF post JAKi and ropeg for prefibrotic and early overt MF. Excited to see what the future brings for these promising agents!

As presented by Joshua Zeidner MD. AZA+VEN+REV in ND-AML 👇

Very unfortunate! Hopefully the subgroup analyses show some benefit in certain patient populations with HR-MDS (?maybe those with excess blasts).